ArticleACS omega2025
DesHDAP2 Shows Significant Synergy with Conventional Antibiotics, Despite Its Relatively Low Potency.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) represent a potential tool in combating increasing antibiotic resistance in bacteria. One promising application of AMPs is their use in antibacterial cocktails along with conventional, small-molecule antibiotics. Here, we investigate the potential antibacterial synergy of our novel histone-derived AMP, DesHDAP2. Consistent with previous studies, DesHDAP2 has relatively low antimicrobial activity on its own, particularly against Gram-negative bacteria. However, DesHDAP2 demonstrates antibacterial synergy with four antibiotics representing several different mechanisms of action, kanamycin, tetracycline, levofloxacin, and polymyxin B. Combinations of DesHDAP2 with these antibiotics also did not show any appreciable cytotoxicity against eukaryotic cells. These results highlight the promise of DesHDAP2 in combination therapy. Moreover, they emphasize the potential application of AMPs that have relatively low activity on their own in therapeutic cocktails with other antibiotics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.